Macrophage-derived Fgl2 dampens antitumor immunity through regulation of FcγRIIB+CD8+ T cells in melanoma
JCI Insight · 2025
DOI: 10.1172/jci.insight.182563 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2025. Verfasst von Kelsey B Bennion und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology PhD program. Hauptthemen laut MEDLINE: Receptors, IgG, CD8-Positive T-Lymphocytes, Melanoma, Macrophages. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Cancer immunotherapy has emerged as a promising therapeutic modality but heterogeneity in patient responsiveness remains. Thus, greater understanding of the immunologic factors that dictate response to immunotherapy is critical to improve patient outcomes. Here, we show that fibrinogen-like protein 2 (Fgl2) is elevated in the setting of melanoma in humans and mice and plays a functional role in inhibiting the CD8 + T cell response. Surprisingly, the tumor itself is not the major cellular source of Fgl2. Instead, we found that macrophage-secreted Fgl2 dampens the CD8 + T cell response through binding and apoptosis of FcγRIIB + CD8 + T cells. This regulation was CD8 + T cell autonomous and not via an antigen-presenting cell intermediary, as absence of Fcgr2b from the CD8 + T cells rendered T cells insensitive to Fgl2 regulation. Fgl2 is robustly expressed by macrophages in 10 cancer types in humans and in 6 syngeneic tumor models in mice, underscoring the clinical relevance of Fgl2 as a therapeutic target to promote T cell activity and improve patient immunotherapeutic response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Biology PhD program.
- Department of Surgery.
- Winship Cancer Institute.
- Immunology and Molecular Pathogenesis PhD program, and.
- Emory Transplant Center, Emory University School of Medicine, Atlanta, Georgia, USA.
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- National Cancer Institute
Zitieren
APA
Bennion, K. B., Miranda R Bazzano, J., Liu, D., Wagener, M., Paulos, C. M., & Ford, M. L. (2025). Macrophage-derived Fgl2 dampens antitumor immunity through regulation of FcγRIIB+CD8+ T cells in melanoma. JCI Insight. https://doi.org/10.1172/jci.insight.182563
Vancouver
Bennion KB, Miranda R Bazzano J, Liu D, Wagener M, Paulos CM, Ford ML. Macrophage-derived Fgl2 dampens antitumor immunity through regulation of FcγRIIB+CD8+ T cells in melanoma. JCI Insight. 2025. doi:10.1172/jci.insight.182563
BibTeX
@article{Bennion2025,
author = {Bennion, Kelsey B and Miranda R Bazzano, Julia and Liu, Danya and Wagener, Maylene and Paulos, Chrystal M and Ford, Mandy L},
title = {Macrophage-derived Fgl2 dampens antitumor immunity through regulation of FcγRIIB+CD8+ T cells in melanoma},
journal = {JCI Insight},
year = {2025},
doi = {10.1172/jci.insight.182563}
}
EUVIMED